Evidence map›Paper›PMID 26768001›Full record

SynthesisDiabetologia2016

Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis.

Stamatina Iliodromiti, Jennifer Sassarini, Thomas W Kelsey, Robert S Lindsay, Naveed Sattar, Scott M Nelson

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Stamatina IliodromitiSchool of Medicine, Glasgow Royal Infirmary, University of Glasgow, Level 2, New Lister Building, Glasgow, G31 2ER, UK. stamatina.iliodromiti@glasgow.ac.uk.
Jennifer SassariniSchool of Medicine, Glasgow Royal Infirmary, University of Glasgow, Level 2, New Lister Building, Glasgow, G31 2ER, UK.
Thomas W KelseyJack Cole Building, University of St Andrews, St Andrews, UK.
Robert S LindsayInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Scott M NelsonSchool of Medicine, Glasgow Royal Infirmary, University of Glasgow, Level 2, New Lister Building, Glasgow, G31 2ER, UK.
University of Glasgow · GBGlasgow Royal Infirmary · GBUniversity of St Andrews · GB

Funding

Chief Scientist Office CZB/4/680Medical Research Council MR/N015177/1
6 · The paper itself

Abstract

aims/hypothesisUniversal screening for gestational diabetes mellitus (GDM) has not been implemented, and this has had substantial clinical implications. Biomarker-directed targeted screening might be feasible. We sought to determine the accuracy of circulating adiponectin for early prediction of GDM.

methodsA systematic review and meta-analysis of the literature to May 2015 identified studies in which circulating adiponectin was measured prior to a diagnosis of GDM. Data on diagnostic accuracy were synthesised by bivariate mixed effects and hierarchical summary receiver operating characteristic (HSROC) models.

resultsThirteen studies met the eligibility criteria, 11 of which (2,865 women; 794 diagnosed with GDM) had extractable data. Circulating adiponectin had a pooled diagnostic odds ratio (DOR) of 6.4 (95% CI 4.1, 9.9), a summary sensitivity of 64.7% (95% CI 51.0%, 76.4%) and a specificity of 77.8% (95% CI 66.4%, 86.1%) for predicting future GDM. The AUC of the HSROC was 0.78 (95% CI 0.74, 0.81). First trimester adiponectin had a pooled sensitivity of 60.3% (95% CI 46.0%, 73.1%), a specificity of 81.3% (95% CI 71.6%, 88.3%) and a DOR of 6.6 (95% CI 3.6, 12.1). The AUC was 0.79 (95% CI 0.75, 0.82). Pooled estimates were similar after adjustment for age, BMI or specific GDM diagnostic threshold. CONCLUSIONS/

interpretationPre-pregnancy and early pregnancy measurement of circulating adiponectin may improve the detection of women at high risk of developing GDM. Prospective evaluation of the combination of adiponectin and maternal characteristics for early identification of those who do and do not require OGTT is warranted.

Indexed as

AdiponectinDiabetes, GestationalFemaleHumansPregnancyAdiponectinADIPOQ protein, humanAdiponectinGestational diabetesMeta-analysisPredictionSystematic review

Identifiers

PMID26768001
PMCPMC4779132
OpenAlexW2229215838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.